1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Strategy

Abbott’s Metabolic Health Biowearable Gets ‘Extremely Positive’ UK Reception; Next Up, US Filing

“We’re so steeped in scientific and medical expertise that we never really learned how to talk to or with regular people,” says Abbott CEO Robert Ford.

 
• By Marion Webb

Lingo, based on Abbott’s FreeStyle Libre diabetes management technology but targeted to the consumer market, works with a companion app to identify user habits that negatively impact their health and guide them in modifying behaviors accordingly. Olivier Ropars, division VP of Lingo Biowearables, discusses the company's recent UK launch and future plans.

• Source: Medtech Insight

It’s been two months since Abbott’s new biosensing wearable Lingo, designed to enable consumers to monitor their metabolic health, made its debut in the United Kingdom. And thus far, the reception in that test market has been “extremely positive,” Olivier Ropars, division vice president of Abbott’s Lingo Biowearables told Medtech Insight at the HLTH conference last week.

Abbott plans to file for US Food and Drug Administration clearance of the device by year-end and then make Lingo more widely available in the UK in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

People On The Move: Appointments at Opella, NèreS, Haleon

 
• By Tom Gallen

A round-up of the latest consumer health industry moves: Opella names France head; NèreS elects president; Haleon has new Saudi GM.

Venture Life Focuses On CHC As It Offloads CDMO

 
• By Tom Gallen

UK-based Venture Life is divesting its CDMO business and some non-core products to focus its attention on growing its consumer health operation.

Danes Get OTC Access To ED Treatment

 
• By Tom Gallen

Navamedic has launched Eroxon in Danish pharmacies giving men in the country OTC access to an ED treatment for the first time.

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By Tom Gallen

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

More from Business

Looming Tariffs Give Boost To Latest PCH Results While Cutting Costs In Response Takes Priority

 
• By Malcolm Spicer

Looming imposition of tariffs by Trump on imports from most every country had an influence on consumers during the January-March period, particularly on online shopping. Increasing product prices on the table, “but our efforts are going to start with cost savings,” says CFO Christine Sacco.

Danes Get OTC Access To ED Treatment

 
• By Tom Gallen

Navamedic has launched Eroxon in Danish pharmacies giving men in the country OTC access to an ED treatment for the first time.

Perrigo Sees Growth Opportunities In Tariff Storm

 
• By Malcolm Spicer

As largest provider of private label/store brand OTCs with “100 plus molecules across 100% price point coverage,” CEO Patrick Lockwood-Taylor says Perrigo’s in position to capitalize as consumers become “more cautious” and look for lower-priced products.